Piotr Kuna, MD, Jadwiga Kaczmarek, MD, Maciej Kupczyk, MD

Slides:

Advertisements

Similar presentations

Clinical trial design, nasal allergen challenge models, and considerations of relevance to pediatrics, nasal polyposis, and different classes of medication

Advertisements

Effect of 2-year placebo-controlled immunotherapy on airway symptoms and medication in patients with birch pollen allergy Monica B. Arvidsson, MD, Olle.

Efficacy and safety of birch pollen immunotherapy for local allergic rhinitis Andrzej Bożek, MD, PhD, Krzysztof Kołodziejczyk, MD, PhD, Jerzy Jarząb,

Allergen immunotherapy: A practice parameter third update

Treatment effect of sublingual immunotherapy tablets and pharmacotherapies for seasonal and perennial allergic rhinitis: Pooled analyses Stephen R. Durham,

Treating acute rhinosinusitis: Comparing efficacy and safety of mometasone furoate nasal spray, amoxicillin, and placebo Eli O. Meltzer, MD, Claus Bachert,

Effects of time, albuterol, and budesonide on the shape of the flow-volume loop in children with asthma Anand C. Patel, MD, Mark L. Van Natta, MHS, James.

Petasol butenoate complex (Ze 339) relieves allergic rhinitis–induced nasal obstruction more effectively than desloratadine Alina F. Dumitru, MD, Mohamed.

Treatment effect of sublingual immunotherapy tablets and pharmacotherapies for seasonal and perennial allergic rhinitis: Pooled analyses Stephen R. Durham,

Optimal dose, efficacy, and safety of once-daily sublingual immunotherapy with a 5– grass pollen tablet for seasonal allergic rhinitis Alain Didier, MD,

Jay A. Lieberman, MD, Faith R. Huang, MD, Hugh A

Santa Jeremy Ono, BA, PhD, Mark B. Abelson, MD

Montelukast treatment may alter the early efficacy of immunotherapy in children with asthma Paweł Majak, MD, PhD, Błażej Rychlik, PhD, Łukasz Pułaski,

Fluticasone furoate nasal spray: A single treatment option for the symptoms of seasonal allergic rhinitis Harold B. Kaiser, MD, Robert M. Naclerio, MD,

Randomized controlled trial of a ragweed allergy immunotherapy tablet in North American and European adults Peter S. Creticos, MD, Jennifer Maloney,

Epicutaneous allergen-specific immunotherapy ameliorates grass pollen–induced rhinoconjunctivitis: A double-blind, placebo-controlled dose escalation.

Epidemic asthma and the role of the fungal mold Alternaria alternata

Dorothy M. Ryan, MD, Stephen J. Fowler, MD, Robert M. Niven, MD

Incident asthma and Mycoplasma pneumoniae: A nationwide cohort study

Preventive effect of nasal filters on allergic rhinitis: A randomized, double-blind, placebo- controlled crossover park study Peter Kenney, BSc, Ole Hilberg,

Bruce M. Prenner, MD, Bobby Q. Lanier, MD, David I

The novel TLR-9 agonist QbG10 shows clinical efficacy in persistent allergic asthma Kai-Michael Beeh, MD, Frank Kanniess, MD, Frank Wagner, MD, Cordula.

Children with allergic and nonallergic rhinitis have a similar risk of asthma Bo Lund Krogsgaard Chawes, MD, Klaus Bønnelykke, MD, PhD, Eskil Kreiner-Møller,

Characterization of pollen antigen–induced IL-31 production by PBMCs in patients with allergic rhinitis Mitsuhiro Okano, MD, Tazuko Fujiwara, BS, Takaya.

Safety and efficacy in children of an SQ-standardized grass allergen tablet for sublingual immunotherapy Albrecht Bufe, PhD, MD, Peter Eberle, MD, Eivy.

Response to sublingual immunotherapy with grass pollen extract: Monotherapy versus combination in a multiallergen extract Sheila M. Amar, MD, Ronald.

Intralymphatic immunotherapy with 2 concomitant allergens, birch and grass: A randomized, double-blind, placebo-controlled trial Laila Hellkvist, MD,

Benefit of Bet v 1 contiguous overlapping peptide immunotherapy persists during first follow-up season Alexander Kettner, PhD, Gilles DellaCorte, MD,

Safety and efficacy of the prostaglandin D2 receptor antagonist AMG 853 in asthmatic patients William W. Busse, MD, Sally E. Wenzel, MD, Eli O. Meltzer,

Peter M. Wolfgram, MD, David B. Allen, MD

Asthma symptom re-emergence after omalizumab withdrawal correlates well with increasing IgE and decreasing pharmacokinetic concentrations Raymond G.

Short- and long-term efficacy of prednisolone for first acute rhinovirus-induced wheezing episode Tuomas Jartti, MD, Riitta Nieminen, BM, Tytti Vuorinen,

Ordinary vibratory angioedema is not generally associated with ADGRE2 mutation Zuotao Zhao, MD, PhD, Sascha Reimann, MD, Shan Wang, MD, Yuhan Wang, MD,

Phillip Lieberman, MD, Michael Tankersley, MD

Is eczema really on the increase worldwide?

Atopic dermatitis: A practice parameter update 2012

Food allergy: A review and update on epidemiology, pathogenesis, diagnosis, prevention, and management Scott H. Sicherer, MD, Hugh A. Sampson, MD Journal.

Efficacy and safety of subcutaneous allergen-specific immunotherapy with depigmented polymerized mite extract in atopic dermatitis Natalija Novak, MD,

Sublingual allergen immunotherapy with a liquid birch pollen product in patients with seasonal allergic rhinoconjunctivitis with or without asthma Oliver.

Allergen-specific immunotherapy with recombinant grass pollen allergens Marek Jutel, MD, Lothar Jaeger, MD, Roland Suck, PhD, Hanns Meyer, Dipl Math,

Claus Bachert, MD, PhD, Cezmi A. Akdis, MD

What is an “eosinophilic phenotype” of asthma?

Treating acute rhinosinusitis: Comparing efficacy and safety of mometasone furoate nasal spray, amoxicillin, and placebo Eli O. Meltzer, MD, Claus Bachert,

H. William Kelly, PharmD Journal of Allergy and Clinical Immunology

Autophagy: Nobel Prize 2016 and allergy and asthma research

Food allergy: Epidemiology, pathogenesis, diagnosis, and treatment

Nasal AMP and histamine challenge within and outside the pollen season in patients with seasonal allergic rhinitis Sriram Vaidyanathan, MBBS, Peter Williamson,

High prevalence of severe asthma in a large random population study

Is intralymphatic immunotherapy ready for clinical use in patients with grass pollen allergy? Marianne Witten, MD, PhD, Hans-Jørgen Malling, MD, Lars.

Sublingual immunotherapy in mite-sensitized children with atopic dermatitis: A randomized, double-blind, placebo-controlled study Giovanni B. Pajno,

Local allergic rhinitis: Allergen tolerance and immunologic changes after preseasonal immunotherapy with grass pollen Carmen Rondón, MD, PhD, Natalia.

Sublingual grass allergen tablet immunotherapy provides sustained clinical benefit with progressive immunologic changes over 2 years Ronald Dahl, MD,

Long-term clinical efficacy in grass pollen–induced rhinoconjunctivitis after treatment with SQ-standardized grass allergy immunotherapy tablet Stephen.

Biology of nasal polyposis

Nasal inflammatory mediators and specific IgE production after nasal challenge with grass pollen in local allergic rhinitis Carmen Rondón, MD, PhD, Javier.

Change in visual analog scale score in a pragmatic randomized cluster trial of allergic rhinitis Philippe-Jean Bousquet, MD, Christophe Combescure, PhD,

Efficacy of 2 months of allergen-specific immunotherapy with Bet v 1–derived contiguous overlapping peptides in patients with allergic rhinoconjunctivitis:

Measles and immunomodulation

Early improvement in basophil sensitivity predicts symptom relief with grass pollen immunotherapy Johannes Martin Schmid, MD, Peter Adler Würtzen, PhD,

Statistical issues in clinical trials that involve the double-blind, placebo-controlled food challenge Vernon M. Chinchilli, PhD, Laura Fisher, MD, Timothy.

Asthma: The past, future, environment, and costs

The correlation between allergic rhinitis and sleep disturbance

Efficacy of a short course of specific immunotherapy in patients with allergic rhinoconjunctivitis to ragweed pollen Piyush Patel, MD, Tom Holdich, MBBS,

The GILL study: Glycerin-induced local reactions in immunotherapy

The effects of an H3 receptor antagonist (PF ) with fexofenadine on reducing allergic rhinitis symptoms Jeffrey R. Stokes, MD, Francisco A. Romero,

Systemic responses after bronchial aspirin challenge in sensitive patients with asthma Joanna S. Makowska, MD, PhD, Janina Grzegorczyk, PhD, Barbara Bienkiewicz,

Advances in pediatric asthma in 2007

Safety and efficacy of repeated monthly carboplatin desensitization

Natural history of cow’s milk allergy

Primary prevention of asthma and allergy

Presentation transcript:

Efficacy and safety of immunotherapy for allergies to Alternaria alternata in children Piotr Kuna, MD, Jadwiga Kaczmarek, MD, Maciej Kupczyk, MD Journal of Allergy and Clinical Immunology Volume 127, Issue 2, Pages 502-508.e6 (February 2011) DOI: 10.1016/j.jaci.2010.11.036 Copyright © 2011 American Academy of Allergy, Asthma & Immunology Terms and Conditions

Fig 1 Study flow chart. QoL, Quality of life. Journal of Allergy and Clinical Immunology 2011 127, 502-508.e6DOI: (10.1016/j.jaci.2010.11.036) Copyright © 2011 American Academy of Allergy, Asthma & Immunology Terms and Conditions

Fig 2 A alternata spore count (spores/m3) during baseline year (2003) and 3 consecutive years (2004, 2005, and 2006) of immunotherapy. Dashed horizontal line indicates the concentration necessary to induce symptoms (100 spores/m3). Journal of Allergy and Clinical Immunology 2011 127, 502-508.e6DOI: (10.1016/j.jaci.2010.11.036) Copyright © 2011 American Academy of Allergy, Asthma & Immunology Terms and Conditions

Fig 3 The weekly average of SMS recorded by patients daily during the season (July, August, and September) at baseline and after 3 consecutive years of immunotherapy (P = .73, .102, <.0001, and <.0001 for baseline, 1, 2, and 3 years of SIT, respectively, active therapy vs placebo, 1-way ANOVA test). The percent reductions, compared with placebo (calculated as area under the curve, [active - placebo]/placebo), were 10.8%, 38.7%, and 63.5% after first, second, and third years of SIT, respectively. Journal of Allergy and Clinical Immunology 2011 127, 502-508.e6DOI: (10.1016/j.jaci.2010.11.036) Copyright © 2011 American Academy of Allergy, Asthma & Immunology Terms and Conditions

Fig 4 Medication score (daily mean ± SEM) at baseline and after consecutive years of immunotherapy (Mann-Whitney U test, active therapy vs placebo). NS, Not significant. Journal of Allergy and Clinical Immunology 2011 127, 502-508.e6DOI: (10.1016/j.jaci.2010.11.036) Copyright © 2011 American Academy of Allergy, Asthma & Immunology Terms and Conditions

Fig 5 Baseline and 4-year symptom scores (individual values, mean ± SEM, described by patients with the use of VAS; see details in the Methods section in this article’s Online Repository) after A alternata nasal challenge in groups given active therapy or placebo (P = .04 for active vs placebo; Mann-Whitney U test). Journal of Allergy and Clinical Immunology 2011 127, 502-508.e6DOI: (10.1016/j.jaci.2010.11.036) Copyright © 2011 American Academy of Allergy, Asthma & Immunology Terms and Conditions

Average asthma (A), rhinitis (B), and conjunctivitis (C) SS (mean ± SEM) recorded by patients with VAS during the season (July, August, and September) at baseline and after consecutive years of immunotherapy (Mann-Whitney U test, active vs placebo). NS, Not significant. Journal of Allergy and Clinical Immunology 2011 127, 502-508.e6DOI: (10.1016/j.jaci.2010.11.036) Copyright © 2011 American Academy of Allergy, Asthma & Immunology Terms and Conditions

QoL (mean ± SEM of scores, Juniper questionnaires) of patients with asthma (A) and rhinoconjunctivitis (B) at baseline and after consecutive years of immunotherapy (∗P < .05, active vs placebo, Mann-Whitney U test). Increase of score in the asthma questionnaire mirrors improvement in QoL, whereas in the rhinoconjunctivitis questionnaire, the situation is the opposite. Journal of Allergy and Clinical Immunology 2011 127, 502-508.e6DOI: (10.1016/j.jaci.2010.11.036) Copyright © 2011 American Academy of Allergy, Asthma & Immunology Terms and Conditions